To evaluate the multiplexing feasibility and assembly quality, Azenta sequenced four E. coli genomes on one PacBio® Sequel™ SMRT cell. This study proves the feasibility of multiplexing and highlights the key advantages of the PacBio Sequel platform as compared to its predecessor, the RSII. Discover the riveting results in this Azenta-exclusive Tech Note.
© 2022 Azenta Life Sciences